This article was originally published in The Gray Sheet
Executive SummarySign three-year renewable collaborative agreement which will allow B-D exclusive rights to in vitro diagnostics developed using Nexagen's proprietary SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology. The two firms will work together on developing compounds to be used in the IVDs; the IVDs will be developed and marketed by B-D. Under the terms of the deal, B-D will provide research funding to Nexagen and has made a $5 mil. equity investment in the privately held, Boulder, Colorado firm. B-D also will pay Nexagen royalties on sales of IVDs resulting from the collaboration. The technology has the "ability to generate huge libraries of up to 1 billion oligonucleotides and to select from those libraries a family of compounds that have the highest affinity and specificity for a given molecular target," according to Nexagen.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.